Antares Pharma (ATRS) Stock Price, News & Analysis

Company Overview

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

Key Stats

• Today's Range: $5.59 to $5.59
• 50-Day Range: $5.59 to $5.59
• 52-Week Range: $3.11 to $5.60
• Volume: 6 shs
• Average Volume: 3.29 million shs
• Market Capitalization: $955.06 million
• P/E Ratio: 23.29
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Antares Pharma Stock Analysis - MarketRank™

Antares Pharma scored higher than 37% of companies evaluated by MarketBeat, and ranked 724th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Antares Pharma.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 175.00%

Earnings Growth

Earnings for Antares Pharma are expected to grow by 175.00% in the coming year, from $0.08 to $0.22 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.15.

Price to Earnings Ratio vs. Sector

The P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.54.

Price to Book Value per Share Ratio

Antares Pharma has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATRS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Antares Pharma does not currently pay a dividend.

Dividend Growth

Antares Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -2.25

Short Interest

There is no current short interest data available for ATRS.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for ATRS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Antares Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Antares Pharma is held by insiders.

Percentage Held by Institutions

50.41% of the stock of Antares Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRS Stock Analysis - Frequently Asked Questions

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) posted its quarterly earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to analyst estimates of $48.52 million. Antares Pharma had a trailing twelve-month return on equity of 7.43% and a net margin of 21.90%.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Meta Platforms (META) and Prospect Capital (PSEC).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:ATRS
• CUSIP: 03664210
• CIK: 1016169
• Web: www.antarespharma.com
• Phone: (609) 359-3020
• Fax: 302-655-5049
• Employees: 201
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.24
• Trailing P/E Ratio: 23.29
• Forward P/E Ratio: 69.88
• P/E Growth: N/A
• Net Income: $46.29 million
• Net Margins: 21.90%
• Pretax Margin: 29.84%
• Return on Equity: 7.43%
• Return on Assets: 4.92%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 3.08
• Quick Ratio: 2.87

Sales & Book Value

• Annual Sales: $183.98 million
• Price / Sales: 5.19
• Cash Flow: $0.13 per share
• Price / Cash Flow: 43.89
• Book Value: $1.03 per share
• Price / Book: 5.43

Miscellaneous

• Outstanding Shares: 170,852,000
• Free Float: 160,772,000
• Market Cap: $955.06 million
• Optionable: Optionable
• Beta: 1.15